FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
News|Slideshows|July 29, 2019
7 Syndromes of Summer
Author(s)Leo Robert
Summer brings sunburn, chemical exposure, allergies, and heat-related ills. Catch up on recent research on some of the unpleasant syndromes of summer.
Advertisement
Summer invites exposure of all kinds--some can be fun but too much can be dangerous. While your patients plan to relax and take some time off during the summer season, take a few minutes of an office visit to discuss potential troubling summer syndromes and recommend moderation in all activities.
Click through the slides below for highlights of research findings specific to summer.
Advertisement
Related to this article
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.
A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.
Advertisement
Advertisement
Trending on Patient Care Online
1
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5